This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad Genetics To Present Three Clinical Studies On Prolaris(R) At The 2014 American Urological Association Annual Meeting

SALT LAKE CITY, May 1, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced clinical data from three studies on Prolaris in prostate cancer patients will be featured at the 2014 American Urological Association (AUA) Annual Meeting, being held May 16–21, 2014, in Orlando, Fla. Prolaris is a novel molecular diagnostic test that accurately predicts cancer-specific death and metastases in men with prostate cancer and is a stronger indicator of clinical outcomes than Gleason score or PSA. In clinical practice, Prolaris is the only test to demonstrate that physicians changed their treatment plans in 65 percent of cases after receiving the test report – 40 percent of patients had a reduction in therapeutic burden, while 25 percent had an increase in therapeutic burden.

At the AUA annual meeting, new data will be presented from the largest clinical validation study to date of any gene-based prognostic test in patients with prostate cancer diagnosed from biopsy. In the second study to be presented, the data will show that the Prolaris test significantly outperformed the current procedure of upgrading to Gleason 3+4 or 4+3 in predicting biochemical recurrence after a radical prostatectomy. The third study will show the prognostic utility of Prolaris based on needle biopsy samples. These studies add to the growing body of outcomes data for Prolaris, which has been extensively validated in 11 clinical studies and more than 5,000 patients. Myriad also will present new data from an investigational diagnostic test for patients with renal cell carcinoma.

"More than ever, we are committed to developing novel molecular diagnostic tests to help to improve patient outcomes, survival and quality of life for people living with prostate and renal cancers," said Michael Brawer, M.D., vice president of Medical Affairs at Myriad. "Our Prolaris test is rapidly becoming the leading test to help the 240,000 men diagnosed with prostate cancer each year to determine if they have aggressive prostate cancer or not. We're also actively developing a new prognostic test for renal cell cancer, which affects 60,000 people every year."
Title: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.
Presenter: Jack Cuzick
Date: Tuesday, May 20, 3:30 p.m. to 5:30 p.m. EDT
Title: Cell Cycle Progression (CCP) outperforms upgrading to Gleason 3+4 or 4+3 in predicting biochemical recurrence after prostatectomy.
Presenter: Matthew Cooperberg
Date: Tuesday, May 20, 3:30 p.m. to 5:30 p.m. EDT
Title: Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy.
Presenter: Jay Bishoff
Date: Tuesday, May 20, 3:30 p.m. to 5:30 p.m. EDT
Title: Cell cycle progression score predicts metastatic progression of clear cell renal cell carcinoma after resection.
Presenter: James Brown
Date: Sunday, May 18, 1:00 p.m. to 3:00 p.m. EDT

About Prolaris ®

Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease progression in men who may be candidates for surveillance and high gene expression is associated with a higher risk of disease progression in patients who may benefit from additional therapy. Prolaris has been proven to predict prostate cancer-specific disease progression in 11 clinical trials with more than 5,000 patients. For more information visit: .

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: .

Myriad, the Myriad logo, Prolaris, Myriad myPath, Myriad myPlan, and Myriad myRisk are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs